Li Chongjie, Zhang Chunxiang, Li Xiuying
Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, People's Republic of China.
School of Pharmacy, Southwest Medical University, LuZhou, 646000, Sichuan, People's Republic of China.
Mol Cell Biochem. 2025 Mar 26. doi: 10.1007/s11010-025-05261-8.
In clonal hematopoiesis of indeterminate potential (CHIP), subpopulations of blood cells carrying somatic mutations expand as the individual ages, and this expansion may elevate risk of blood cancers as well as cardiovascular disease. Individuals at higher risk of CHIP and therefore of CHIP-associated disease can be identified through mutational profiling, and the apparently central role of inflammation in CHIP-associated disease has emerged as a potential therapeutic target. While CHIP is often associated with negative health outcomes, emerging evidence suggests that some CHIP-related mutations may also exert beneficial effects, indicating a more complex role in human health. This review examines current understanding of the epidemiology and clinical significance of CHIP and the role of inflammation in driving its association with disease risk. It explores the mechanisms linking CHIP to inflammation and risk of cardiovascular and other diseases, as well as the potential of personalizing therapies against those diseases for individuals with CHIP.
在不确定潜能的克隆性造血（CHIP）中，携带体细胞突变的血细胞亚群会随着个体年龄增长而扩增，这种扩增可能会增加患血癌以及心血管疾病的风险。通过突变谱分析可以识别出患CHIP风险较高以及因此患CHIP相关疾病风险较高的个体，并且炎症在CHIP相关疾病中明显的核心作用已成为一个潜在的治疗靶点。虽然CHIP通常与不良健康结局相关，但新出现的证据表明，一些与CHIP相关的突变也可能发挥有益作用，这表明其在人类健康中的作用更为复杂。本综述探讨了目前对CHIP的流行病学和临床意义以及炎症在推动其与疾病风险关联中所起作用的理解。它还探讨了将CHIP与炎症以及心血管疾病和其他疾病风险联系起来的机制，以及针对患有CHIP的个体对这些疾病进行个性化治疗的潜力。
